News Headline Summary

Roche's Perjeta (ROG VX) significantly extends survival in people with HER2-positive metastatic breast cancer

Reaction details (12:03)

- In an immediate reaction company shares moved 0.16% higher from CHF 185.298 to CHF 185.601

10 Dec 2012 - 11:59 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: